Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
September 14, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview...
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
September 13, 2021 06:00 ET
|
Matinas BioPharma Holdings, Inc.
– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of...
Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
August 16, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
August 10, 2021 06:31 ET
|
Matinas BioPharma Holdings, Inc.
– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from...
Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
August 03, 2021 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
July 27, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
May 20, 2021 08:00 ET
|
Matinas BioPharma Holdings, Inc.
Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs David R. Boulware, M.D., MPH, Professor of Medicine, Infectious Disease and...
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 06:30 ET
|
Matinas BioPharma Holdings, Inc.
– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from...
Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
April 28, 2021 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
April 27, 2021 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...